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Summary Changes in integrin expression have been shown to be important forthe growth and metastatic capacity of melanoma cells. In this
study, we have examined the expression of av integrins by three uveal and four cutaneous malanoma lines. No lines expressed avP6 and
onlyTXM13, a cutaneous line, expressed av,B8. All linesexpressed avf5 andavP3 (four out offourcutaneous, two out ofthree uveal) oravfi1
(OM431, an uveal line). Thus, OM431 is the second uveal melanoma we have described that expresses avIl and this, we report again,
functions as an alternative vitronectin/fibronectin receptor. Subcutaneous growth of cell lines in athymic mice correlated with an avp3-positive,
avI1 -negative phenotype. Analysis of clinical material from cutaneous melanoma showed that although av expression was increased in 88%
of metastases, this could not all be explained by up-regulation of av,B3, with only 2 out of eight skin metastases expressing this heterodimer.
Using antibody SZ.21, which as we report here works in archival material, only 1 out of 15 uveal metastases expressed detectable P3. Thus,
acquisition of avP3 expression, which has been implicated in cutaneous melanoma progression, may not be required for development of
metastases from uveal melanoma or indeed for skin, as distinct from lymph node, metastases of cutaneous melanoma.
Keywords: cell adhesion; ocular melanoma; skin melanoma
Cutaneous melanoma is a tumour type whose incidence in
Caucasian populations has increased dramatically over the past
80 years. The cancer generally is considered to evolve through
a series of distinct pathological steps (Mastrangelo et al, 1985).
Thus, melanocytic naevi progress to flat tumours that grow hori-
zontally (radial growth phase, RGP) before they acquire the
capacity to invade vertically (vertical growth phase, VGP) and
then metastasize. Ocular melanomas, of which the most common
are uveal melanomas, occur at about 10% the frequency of cuta-
neous tumours. These cancers do not seem to progress through the
same stages of evolution, but the histological type of uveal
melanoma determines the probable metastatic propensity. Thus,
the 'spindle' forms rarely metastasize, whereas the 'epithelioid'
types are highly metastatic and then usually spread preferentially
to the liver (Shields and Shields, 1992).
Disseminating cancer cells must interact with the extracellular
matrix and this interaction is mediated principally by cell surface
adhesion receptors, termed integrins (Hynes, 1992). Integrins are
heterodimeric glycoproteins, consisting of a-chains non-cova-
lently associated with ,B-chains, which are expressed at the cell
surface. Several studies have examined expression of the integrin
family of adhesion molecules in cutaneous melanoma at various
stages of tumour development. Levels of expression of different
integrin subunits have been reported to increase during tumour
progression, including a2,1 (Klein et al, 1991), a3 1 (Natali et al,
1993), a4pl (Schadendorf et al, 1993), a5,Bl (Danen et al, 1994),
a6P1 (Natali et al, 1991) and a7 31(Kramer et al, 1991). However,
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the integrin whose levels of expression have correlated most
consistently with progression is the classical vitronectin receptor
avP3 (Cheresh and Spiro, 1987). Thus, Albelda and colleagues
(1990) noted that the ,3 subunit was only detected on VGP and
metastases of cutaneous melanoma. This study almost certainly
documented the appearance of avP3 as similar findings were
described using an avP3-specific antibody in which it was noted
that expression of this heterodimer was higher in cutaneous
metastases than expression on less advanced tumours (Danen etal,
1994; Si and Hersey, 1994). These data suggest that av,3 may
play an active role in the progression ofcutaneous melanoma.
In vitro studies have supportedthis possibility. The av-deficient
M21-L human melanoma cell line grew very poorly in nude mice
compared with either the av-positive parental line or a line in
which av expression was restored by transfection with a full-
length av cDNA (Felding-Habermann et al, 1992). Treatment of
animals with the av-blocking antibody 17E6 inhibited the growth
of the av-positive M21 melanoma cell line (Mitjans et al, 1995).
Earlier studies by Boukerche and colleagues (1994) showed that
the co-injection of antibody LYP18, which cross-reacts with both
aIIb133 and avP3, inhibited tumour growth of the human
melanoma cell line M3Dau (Boukerche et al, 1989). We have
shown that the ability of human melanoma cell lines to form
subcutaneous tumours in athymic nude mice correlated with levels
of expression of avP3 (Marshall et al, 1991). However, av,3-
negative cutaneous melanoma cell lines have metastasized in nude
mice (Boukerche et al, 1994; Danen et al, 1995), suggesting that
expression of this heterodimer is not obligatory for malignant
behaviour.
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Table 1 Monoclonal antibodies used in this study
Antigen Antibody Reference Source
a2 P1E6 Wayner et al (1988) Life Technologies, Paisley, UK
a3 J143 Fradet et al (1984) Dr L Old (Memoral Sloan Kettering, NY, USA)
a3 P1B5 Wayner et al (1988) Life Technologies, Paisley, UK
a4 P4G9 Wayner et al (1989) Life Technologies, Paisley, UK
a4 7.2 Marshall et al (unpublished) Produced in house
a5 P1D6 Wayner et al (1988) Life Technologies, Paisley, UK
a6 GOH3 (rat) Sonnenberg et al (1987) Serotec, Oxford, UK
av 13C2 Davies et al (1989) Dr MA Horton (Middlesex Hospital, London, UK)
av 17E6 Mitjans et al (1995) Dr SL Goodman (Merck KGaA, Germany)
acv P2W7 Marshall et al (unpublished) Produced in house
p1 MAR4 Pellegrini et al (1992) Dr S Martignone (Istituto Nazionale per lo Studio e la Curio dei Tumori, Milan, Italy)
31 P4C10 Carter et al (1990) Life Technologies, Paisley, UK
3 4B7 Marshall et al (unpublished) Produced in house
33 SZ.21 Serotec (Cat. No. MCA 583)
av,B3 23C6 Davies et al (1989) Dr MA Horton
av,B3 LM609 Cheresh and Spiro (1987) Chemicon International, Harrow, UK
avP5 P3G2 Wayner et al (1991) Dr DA Cheresh (Scripps Research Institute, LaJolla, CA, USA)
av35 P1 F6 Weinacker et al (1994) Life Technologies, Paisley, UK
av,B6 E7P6 Weinacker et al (1994) Dr D Sheppard (UCSF, San Francisco, USA)
avP8 SN1 Nishimura et al (1994) Dr S Nishimura (UCSF, San Francisco, USA)
200 kDa protein 14E2 Mitjans et al (1995) Dr SL Goodman (Merck KGaA, Germany)
The av,3-integrin is not the only avp-heterodimer expressed
by melanoma cells. We found that a uveal melanoma-derived cell
line, which lacked av,3, expressed av,l, which functioned as a
receptor forvitronectin, fibrinogen and fibronectin (Marshall et al,
1991). As there are no reagents that specifically recognize the
xv,Bl-heterodimer, confirmation of avpl expression was by
immunoprecipitation with antibodies to av followed by immuno-
logical analysis of the co-precipitated PI-sized subunit. Thus, the
frequency of expression of av,l in either cutaneous or ocular
melanoma is unknown.
Five different avf-heterodimers have been described to date:
av[B1, avP3, av,B5, avP6 and av[8 (Hynes, 1992). The relative
expression of these various heterodimers by cells derived from a
single histological origin has not been studied in a systematic
fashion. In the present study, we have examined integrin expres-
sion, with particular emphasis on av,-heterodimers, in a panel of
cell lines derived from uveal and cutaneous melanomas and in
clinical material from both types ofcancer.
MATERIAL AND METHODS
Cell lines and antibodies
The antibodies used in this study are detailed in Table 1. Six uveal
melanoma lines were analysed: V(+)B2 and V(+)D9H are high
avfl-expressing derivatives of VUP (Marshall et al, 1995),
whereas OM431, SP6.5 and OCM-1 were gifts from Professor
D Alberts (Massachusetts Eye and Ear Infirmary, Boston, MS,
USA). The cutaneous melanoma cell lines examined were TXM13
(supplied by Dr IJ Fidler, Houston, TX, USA), and Mel 8, Mel 17
and XP44 (gifts from Dr NGJ Jaspers, Rotterdam, The
Netherlands; supplied by Dr M Meuth, ICRF, London).
Fluorocytometric analysis
Cell lines were detached from culture dishes with trypsin (0.25%
w/v)/EDTA (5 mM) solution and allowed to recover for 30 min
at 370°C in complete medium. Cells were washed in ice-cold
phosphate buffered saline (PBS; pH 7.2) supplemented with
bovine serum albumin (0.1%, w/v) and sodium azide (0.1% w/v)
(wash buffer). Aliquots of cells (50 pl containing approximately
2 x 105 cells) were incubated with primary antibody. After 45 min
incubation on ice, cells were washed three times in ice-cold wash
buffer and 50 ,ul of FITC-conjugated rabbit anti-mouse (RAM-
FITC) IgG was added (1/40 dilution in wash buffer DAKO F232;
Dako, High Wycombe, UK). After 30 min on ice, cells were
washed three more times before analysis on a FACScan flow
cytometer fitted with Lysis II software (Becton-Dickinson,
Oxford, UK). To minimize interexperimental variation, the
FACScan laser was adjusted suchthat anexternal standard (Coulter
Standard Brite fluorospheres; Coulter Electronics) always gave the
same fluorescence intensity. All analyses were repeated on three
separate days and the median fluorescence recorded each time.
Immunoprecipitation
Theavo-heterodimers expressed by four uveal melanoma-derived
cell lines, V(+)B2, OM431, OCM-I and SP6.5, were analysed by
immunoprecipitation of surface-iodinated, NP40-detergent-lysed
cell extracts as described previously (Marshall et al, 1991).
Immunoprecipitates were separated on SDS-PAGE gels (6% w/v
acrylamide; Protogel, National Diagnostics, Hull, UK) under
non-reducing conditions.
Adhesion assays
The wells of96-well plates (Falcon 3912; Becton Dickinson, UK)
were coated overnight at 4°C with human fibronectin (50 ,ul at
10,g ml-'; Sigma, UK), vitronectin (50gl at 10gg ml-'; Life
Sciences, Gibco-BRL, Paisley, UK) or bovine serum albumin
(BSA) [0.1% w/v phosphate buffered saline (PBS) pH 7.2].
Unbound protein was flicked-off and the wells flooded with BSA
solution for 60 min at 37°C to block residual binding sites.
Melanoma cells, detached using trypsin/EDTA solution, were
5'Cr-labelled and, after washing in serum-free growth medium,
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Table 2 Integrin expression of uveal and cutaneous melanoma cell lines as determined by flow cytometry
Ocular melanoma cell lines Cutaneous melanoma cell lines
Integrin Antibody VUPa OM431 OCMi SP6.5 TXM13 Mel 8 Mel 17 XP44
av P2W7 14±6b 33±23 200±29 54±5.2 260±54 117±16 172±13 215±79
avP3 23C6 1.7±2.9 2.3±2.1 158±28 26±14 145±56 115±11 152±8 174±32
avP5 P3G2 4.7±6.4 5.6±3.2 20.7±21 7.7±1.5 31±27 9.3±8.1 12±14 12±8.2
av,6 E7P6 0 1.0 ±1.0 0 0 4± 7.5 3± 5.2 0 0
av38 SN1 0 0.7±1.2 0.3±0.6 0.3±0.6 29±19 1.0±1.0 3±1.2 1±0
a4 7.2 0 3.0±1.0 13.7±8 5.0±5.6 43±18 6.3±0.6 16±2.3 36±11
a5 P1D6 17±3.6 2.7±1.5 9.3±9.3 4.7±1.5 43±8 14±12 6±0.6 10±10
p1 MAR4 70±7.8 73±35 91 ±31 91±15 494±59 82±7.5 108±42 300±63
aFour human uveal melanoma-derived cell lines (VUP, OM431, OCMI1 and SP6.5) and four human cutaneous melanoma-derved cell lines (TXM13, Mel 8,
Mel 17 and XP44) were analysed for integrin expression byflow cytometry. Cells were labelled with antibodies for 45 min at40C, washed in wash buffer, and
bound antibody detected with RAM-FITC. bThe negative control (cells labelled with RAM-FITC only) median fluorescence was subtracted from the median
fluorescence of the antibody-labelled samples. Data shown are the averages of three separate experiments ±1 s.d.
were added in 50gl volumes (1-2 x 104 cells per well) to quad-
ruplicate wells. The plates were incubated for 60 min at 37°C
before unattached cells were removed by gently flicking-out well
contents and washing the plates twice by total immersion in a bath
of PBS supplemented with calcium chloride (1 mM) and magne-
sium chloride (0.5 mM). The per cent adhesion was calculated
from the residual radioactivity (c.p.m.) associated with the wells.
Background (adhesion to BSA-coated wells) was usually < 2% of
input and was subtracted from all results. In some experiments,
extracellular matrix (ECM)-coated plates were placed on ice and
25 gl ofanti-integrin antibodies were added to the wells before the
addition of 25 ,ul volumes of twofold concentrated cells. After
10 min incubation on ice the plates were placed at 37°C for60 min
and the assay continued as described above.
Assessment of tumorigenicity
A total of 1-2 x 106 melanoma cells was injected subcutaneously
into the right flank of athymic nude mice. Mice were monitored
weekly for up to 12 months for the appearance of palpable
tumours.
Immunohistochemical analysis of melanoma tissues
Fresh material from uveal, cutaneous and local nodal tissue was
obtained at surgery, snap-frozen inliquid nitrogen and stored subse-
quently at - 70°C. Tissue was examined from 21 benign cutaneous
naevi (only one ofwhich hadhistological features ofatypia, the rest
were dermal cellular naevi), nine cutaneous melanomas in radial
growth phase, eight cutaneous melanomas that had entered vertical
growth phase, eight cutaneous metastases and eight lymph node
metastases. Material was obtained from 13 primary uveal ocular
melanomas at enucleation. The uveal melanoma lesions varied
histologically, being ofboth spindle and epithelioid type as well as
a mixture of these cells. No frozen tissue from metastatic lesions
was available butparaffin-embedded archival material representing
15 different metastases from six individual patients with uveal
melanoma metastases was examined.
For the fresh tissue, cryostat sections (5 ,im) were taken on to
poly-L-lysine coated slides, air-dried and stored at - 20°C. Primary
antibodies were applied to sections for60 min atroom temperature.
Aftergentlewashing in PBS, astandard peroxidase/anti-peroxidase
technique was used according to the manufacturer's instructions
(Vectastain Kit, Vector Laboratories, Peterborough, UK). Bound
antibody was detected with 3-amino 9-ethyl carbazoyl (AEC),
which gives rise to a red chromogen. For archival material, slides
were dewaxed and endogenous peroxidase blocked with 0.05%
hydrogen peroxide in methanol for 15 min. (For detection of P3,
slides were placed into boiling 0.O1M sodium citrate buffer pH 6.0
in a pressure cooker and put under pressure for 2 min. The buffer
was flushed away and slides washed in tap water.) Sections were
blocked with 20% normal rabbit serum for 15 min before adding
the primary antibodies 4B7 (anti-PI; undiluted supematant) or
SZ.21 (anti-P3; 1:100 dilution in TBS) for 60 min. After washing
in TBS, a standard avidin-biotin-chromogen method was used,
and slides developedby diaminobenzidene toproduce an insoluble
brown end-product.
RESULTS
Expression of integrins in melanoma cell lines
determined by flow cytometry
Data from a series of individual experiments are summarized in
Table 2. Expression of av and 31 was seen in all lines. Although
theavp3-integrin was expressed by all cutaneous melanoma lines,
only two out of four uveal melanoma lines expressed it (OCM1
and SP6.5). Of the eight lines detailed in Table 2, none expressed
significant amounts of either avj6 or av8, except TXM13,
which appeared to express avP8. Expression of av,B5 was rela-
tively low on all cell lines although level ofexpression ofthis inte-
grin may be variable.
Immunoprecipitation of uveal melanoma av-integrins
SP6.5, OCM1 and OM431 uveal lines and, for comparison, the
VUP-derived subline V + B2 were analysed by immunoprecipita-
tion. Figure 1 shows that both SP6.5 and OCM-1 express av03
whereas V + B2 and OM431 do not. Immunoprecipitation with
antibody to av (13C2) coprecipitated a (1-sized band from both
OM431 andV(+)B2 but notfrom the SP6.5 orOCM-I cell lines. It
appears that OM431 is the second uveal melanoma cell line that
we have shown to lack avP3 but to express avil (Marshall et al,
1991). Figure 1 also confirms the flow cytometry data (Table 2)
that avP5 is expressed weakly by OM431, SP6.5, OCM-I and, as
reported previously, V + B2 (Marshall, 1995).
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Figure 1 Immunoprecipitation analysis of av integrins expressed by uveal
melanoma cell lines. NP40-detergent lysates of surface-iodinated OCM-1,
SP6.5, OM431 and V(+)B2 cells were incubated with 13C2 (anti-av), 23C6
(anti-avfP3) and P3G2 (anti-avP5). Resulting immunocomplexes were
collected on protein A-Sepharose beads coated with rabbit anti-mouse IgG
and analysed on 6% SDS-PAGE gels under non-reducing conditions.
Relative molecular weights (x 103 kDa) are indicated
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12
VUP
T
Function of avp-integrins in uveal melanoma cell lines
The avil expressed by V(+)B2 binds to vitronectin and co-
operates with a5p1 to bind to fibronectin (Marshall, 1995). To
examine whether the avpl expressed by OM431 cells manifested
a similar range of activities 51Cr-labelled cells were allowed to
adhere to vitronectin or fibronectin in the presence or absence of
various anti-integrin antibodies. For comparison, the uveal
melanoma lines VUP (low av3l-expressing) and V(+)B2 (high
av,Bl-expressing) as well as SP6.5 (avil-negative, av,B3-posi-
tive) were also studied. Figure 2 shows that, in the presence of a
class-matched negative control antibody (14E2), all four cell lines
boundtovitronectin, abinding which was reducedby > 80% in the
presence of the av-blocking antibody, 17E6. The adhesion to
vitronectinby SP6.5 appeared to be mediated principally byavP3-
and avp5-dependent mechanisms as shown by the inhibition by
the antibodies LM609 (39.6% inhibition) andP3G2 (14.4% inhibi-
tion) (Figure 2). In contrast, the anti-av,3 antibody LM609 hadno
effect on the adhesion to vitronectin of the av,3-negative lines
VUP, V(+)B2 and OM431.
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Figure 2 Adhesion of uveal melanoma cell lines to vitronectin. Cells were chromium 51Cr-labelled and added in the presence or absence of specific antibodies
(see Materials and methods) to fibronectin-coated 96-well plates. After 60 min at 370C non-adherent cells were washed away and adhesion was determined by
measuring residual radioactivity (c.p.m.)
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The adhesion ofOM431 to vitronectin was av-dependent as the
presence of an av-blocking antibody (17E6) reduced adhesion by
86% (Figure 2). The antibodies P3G2(avP5-blocking) and P4C1O
((51-blocking) inhibited adhesion to vitronectin by 48.1% and
29.2% respectively (Figure 2). These data show that OM431 binds
to vitronectin via avP5- and axv,1-dependent mechanisms,
although it appears that the avP5 heterodimer may be the domi-
nant vitronectin receptor.
Adhesion ofV(+)B2 cells to vitronectin was inhibited by 17E6
(88.6%) and P4C1O (82.7%) but not by P3G2 (anti-av,5)
(Figure 2). However, the combination ofP3G2 and P4C1O inhib-
ited adhesion of V(+)B2 by 94.2%, suggesting that although
binding of V(+)B2 to vitronectin is mediated predominantly via
avpil the low level of avP5 expressed also functions as a
vitronectin receptor. Adhesion to vitronectin by the low av1-
expressing parental line VUP was inhibited by 78.0% by anti-
body P3G2(anti-avP5) and 14.1% by antibody P4C10 (anti- 1),
whereas the combination of P3G2 and P4C1O inhibited
completely adhesion to vitronectin. These data appear to suggest
that, in contrast to V(+)B2, avP5 is the major vitronectin
receptor on the VUP cell line.
All of the uveal melanoma cell lines tested bound well to
fibronectin, as illustrated inFigure 3. Wehave shown previously that
V(+)B2 binds to fibronectin through the cooperative action ofavpl
and a5PI (Marshall, 1995). Adhesion ofVUP and OM431 appeared
to be via a similarmechanism. Thus, PID6 (anti-aS) when combined
with 17E6 reduced adhesion to fibronectin of VUP and OM431 by
62.8% and 54.0% respectively. The inability of PiB5 (anti-a3) to
affect adhesion to fibronectin, even when used in combination with
17E6, suggests that a3,B1 is not a major receptor for fibronectin in
these unveal melanoma cell lines. Therefore, it appears that OM431,
VUP andV(+)B2 adhere to fibronectin viaanavfl/a5pl-dependent
mechanism. The adherence of SP6.5 cells to fibronectin also
appeared to utilize a combination of integrins (Figure 3). Thus, the
only single antibody to inhibit adhesion of SP6.5 to fibronectin
significantly was 17E6 (29.1% inhibition). Combination of 17E6
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with PiB5 or P1D6 caused afurther inhibition ofadhesion to 39.9%
and 43.4% respectively. However, maximum inhibition (80.4%) of
adhesion to fibronectin required the co-incubation of 17E6, PlD6
and P4C1O antibodies (Figure 3).
In vivo behaviour of uveal and cutaneous melanoma
cell lines
Table 3 details theability ofsixuveal andthreecutaneous melanoma
cell lines to form progressively growing subcutaneous xenografts in
athymic nude mice. The VUP line and the two high avpl-
expressing derivatives V(+)B2 and V(+)D9H failed to form
tumours. Twoofeightmiceinoculatedwith OM431 developed slow
growing tumours, which reached 10mm diameter after 210 and
330 days post inoculum. The remaining cell lines OCM-1, SP6.5,
Mel 8, Mel 17 andXP44 werehighly tumorigenic, forming tumours
in 50-100% of animals (Table 3). Thus, the av,B3-positive uveal
melanomacell lines OCM-I and SP6.5 were more tumorigenic than
the avil-positive uveal melanoma lines VUP, V(+)B2, V(+)D9H
and OM431, which were eitherpoorly ornon-tumorigenic.
Expression of integrins by cutaneous and uveal
melanoma tissues
Cryostat sections ofcutaneous anduveal melanoma tumourtissues
were analysed by immunohistochemistry for the expression ofa2,
a3, a4, aS, a6, av, av,B3 and av,B5 (Table 4).
The major integrin subunits expressed in primary uveal
melanoma were a3 and av, which were present on 13 out of 13
samples. The integrin av,5 was detected on 11 out of 12 tumours
and was possibly the major av,B-heterodimer present as av,3 was
not found on any ofthe 13 tumours analysed. Analysis of 15 uveal
melanoma metastases showed thatonly one ofthe tumours was03-
positive. An internal positive control was often present on these
sections as blood vessels stainedpositively for03 (datanot shown).
In contrast, expression of , 1 was detected in 8 out of 15 uveal
melanoma metastases in this small series ofarchival material.
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Figure 3 Adhesion of uveal melanoma cell lines to fibronectin. Cells were chromium 5'Cr-labelled and added in the presence or absence of specific antibodies
(see Materials and methods) to vitronectin-coated 96-well plates. After 60 min at 370C non-adherent cells were washed away and adhesion determined by
measuring residual radioactivity (c.p.m.)
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Table 3 Tumorigenicity of uveal and cutaneous melanoma cell lines in
athymic nude mice
Cell line No. of micea No. with tumours % Tumorigenicity
VUP 12 0 0
V(+)B2 12 0 0
V(+)D9H 12 0 0
OM431 8 2b 25
OCM 10 5 50
SP6.5 15 15 100
Mel 8c 4 4 100
Mel 17 10 10 100
XP44 10 9 90
aGroups of Balb/C nude mice were given s.c. injections of 2 x 106 (200gIl)
melanoma cells. Mice were monitored weekly for development of palpable
tumours. bTumours achieved a diameter of 10 mm, 210 and 330 days post
inoculum. cOnly 1 x 106 Mel 8 cells were injected.
In cutaneous melanoma, the expression of a3 and av was not
detectable on benign lesions but was expressed on almost all ofthe
metastases. The a4- and a5-subunits were absent on primary cuta-
neous lesions but were present on seven out ofnine and five out of
nine oflymph node metastases, respectively, but on only one out of
eight skin metastases (Table 4). Expression of avP3 was also
confined to metastases being detected on five out of nine lymph
node and two out ofeight skin metastases. In contrast, expression of
avP5 was higheron the primary lesion (six outoftennaevi, fourout
of seven VGP) compared with metastases (one out of eight skin
metastases); 10 outof 17 vs 1 out of8 (P.0.04, Fisher's exact test).
DISCUSSION
For malignant cells to metastasize they must decrease their attach-
ment to neighbouring cells. In addition, as maximum motility
requires intermediate adhesiveness (Palacek et al, 1997) they may
also require reduced adhesion to underlying ECM proteins. This
may partly explain why development ofbreast andcolorectal cancer
is often associated with reduced or aberrant expression of a2, a3
and a6 (for references see Gui et al, 1997). However, ligation of
integrins to the ECM can generate survival signals (reviewed by
Meredith and Schwartz, 1996) and, thus, increased expression or de
novo expression ofspecific integrins could also promote cancer.
Cutaneous melanoma is an example of a cancer in which
tumour progression correlates with a net gain in several integrins,
most notably av,B3 (Albelda et al, 1990; Danen et al, 1994; 1995;
Si and Hersey, 1994; Natali et al, 1997). Although 10% of
melanoma occurs in the eye, the majority in the uvea (Shields and
Shields, 1992), very little has been documented on the integrins
expressed by these tumours. We have therefore compared the
expression ofintegrins by uveal vs cutaneous melanoma cell lines
and tissues.
Using flow cytometry (Table 2) and immunoprecipitation
(Figure 1) we now show that OM431 is the second uveal melanoma
that lacks av,3 but expresses av,B1 a vitronectin/fibronectin
receptor (Figures 2 and 3). However, expression of xv,31 is not
universal for all uveal lines as it was not detected in SP6.5 or
OCM-1, which instead expressavP3 (Figure 1).
Analysis ofthe tumorigenicity ofthe cell lines (Table 3) revealed
that the avP3-expressing lines, regardless of uveal or cutaneous
origin, were highly tumorigenic, forming xenografts 50-100% of
inoculated animals. In contrast the av,B1-positive lines were either
poorly or non-tumorigenic. In addition, using flow cytometry we
have measured expression of av,5, avP6 and avP8 on the nine
cutaneous melanoma cell lines already examined for av,B3 expres-
sion (Marshall etal, 1991). Together with thedatareportedhere, we
have found thatformation ofsubcutaneous xenografts by 17 human
(cutaneous and uveal) melanoma lines correlates with an avP3-
positive, av,B1-negative phenotype. Thus, ourdatamay suggestthat
loss ofav Il by the VUP and OM431 lines may promote xenograft
formation. We have found no correlation between tumorigenicity
and expression of avP35 or avP8 (avP6 was not expressed by
melanoma cell lines; Marshall and Hart, 1996).
In a recent study, Natali and colleagues (1997) failed to detect
any av-integrins on eight uveal melanomas. However, our
analysis ofuveal melanoma clinical material confirmed aprevious
report (ten Berge et al, 1993) that primary uveal melanomas
appear to be avP3 negative, av,B5 positive. However, these
workers also showed that two ofthree metastases expressed av,B3,
which we did not observe in our own series. Using the antibodies
SZ.21 (anti-53) and4B7 (anti-p1), which as reported here work on
paraffin-embedded material, only 1 out of 15 uveal melanoma
metastases were 33-positive, whereas 8 out of 15 were P1 positive.
Thus, unlike cutaneous melanoma, we found no positive correla-
tion between expression ofavP3 and uveal melanoma metastases.
Table 4 Immunohistochemical analysis of integrin expression by uveal and cutaneous melanomas
Benign Radial Vertical Nodal Skin Uveal Primary Uvealc
Naevusa Growth Growth Metastasis Metastasis Melanoma Metastasis
Phasea Phasea
cX2b 4/21 0/9 1/8 3/6 2/8 2/7 -
a3 0/21 1/9 4/8 7/9 6/8 13/13 -
a4 0/21 0/9 0/8 7/9 1/8 0/13 -
a5 0/9 0/9 0/8 5/9 1/8 0/13 -
av,B3 0/21 1/9 1/8 5/9 2/8 0/13 -
av,B5 6/10 - 4/7 - 1/6 11/12 -
pi
- - - - - - 8/15
P3 - - - - - - 1/15
aThe cutaneous melanoma tumours were assessed for histological stage. bFrozen cryostat sections were thawed, fixed in acetone (10 minutes at
-200C), air-dried and labelled with antibodies to a2 (P1E6, 1:100), a3 (J143, 1:100), a4 (P4G9, 1:100), a5 (P1D6, 1:100), a6 (GOH3, 1:100), av
(13C2, undiluted supernatant), avP3 (23C6, undiluted supernatant), avP5 (P3G2, 1:100), f1 (4B7, undiluted supernatant) andf3 (SZ.21, 1:100)
CParaffin-embedded material.
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We detected integrin av[3 on five ofnine lymph node and two of
eight skin metastases (Table 4), although it should be noted that
Natali etal (1997) did notnote adifference inexpression ofthis inte-
grin between these types of metastases. In addition unlike previous
reports (Albeldaetal, 1990; Si andHersey, 1994), only oneoutofthe
eight vertical growth phase lesions was found to be av,3 positive.
Expression ofavP5 was higher in the primary lesions (six out often
naevi, fourout ofseven VGP) than on the metastases (one out ofsix
skin metastases) in agreement with the dataofDanen andcolleagues
(1995). However, although most metastases from cutaneous
melanoma had increased levels of av integrins, this was not always
accounted for by a commensurate increase in eitheravP5 or av,3
(Table 4), suggesting thatnon-,3 av-integrins were up-regulated.
Like others, we found that a3,B1 (Natali et al, 1993),
a4p1(Schadendorf etal, 1993), andac51 (Danen etal, 1994) show
an increased expression on more advanced stages of cutaneous
melanoma; particularly on the metastases (Table 4). It may be
significant that expression ofa4 and aS was detected on seven out
of nine and five out of nine lymph node metastases, respectively,
but only on one out ofeight skin metastases (Table 4). These data
could suggest that expression of these integrins may increase the
propensity of melanoma cells to colonize lymph nodes partly,
perhaps, by usinga4p1 to adhere to VCAM-1 (Mould et al, 1994).
The observation by several groups (Albelda et al, 1990; Danen
et al, 1994; 1995; Si and Hersey, 1994; Natali et al, 1997) and
ourselves that av,3 expression is increased in the later stages of
cutaneous melanoma is consistent with this heterodimer having an
active role in malignancy. Several functions have been ascribed to
avP3 that may contribute to such a mechanism. Thus, it has been
reported that avP3 may cause retention of melanoma cells in
lymph nodes through binding to lymph node vitronectin (Nip et al,
1992), whereas ligation ofavP3 has resulted in increased expres-
sion ofthe metalloproteinase MMP2 (72 kDa type IV collagenase)
(Seftor et al, 1992). Recently, Brooks and colleagues (1996) have
reported that av,B3 bound to, and thus located, MMP2 at the
surface ofinvasive cells. Moreover, avP3, which is not normally a
receptor for interstitial collagen, binds to denatured (for example
collagenase-digested) collagen type I and in doing so may provide
survival signals to melanoma cells (Montgomery et al, 1994).
Thus, in addition to its role as a major adhesive and migratory
integrin (Marshall and Hart, 1996), av,3 may have other func-
tions during melanoma development.
In conclusion, an avP3-positive, av,1-negative phenotype is
associated with the capacity of cutaneous or uveal melanoma cell
lines to form xenografts in nude mice. However, in clinical mate-
rial, although av,B3 was expressed by > 50% nodal metastases, the
majority of uveal melanoma metastases and cutaneous melanoma
skin metastases lacked detectable avP3, suggesting that expres-
sion of this integrin may not be a prerequisite for formation of
either ofthese melanoma lesions.
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